Comparing Haegarda vs Takhzyro
Haegarda (C1 esterase inhibitor (human)) | Takhzyro (lanadelumab) |
|
---|
Haegarda (C1 esterase inhibitor (human)) | Takhzyro (lanadelumab) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Haegarda works by replacing missing C1 protein in the blood of adults and children over the age of 6 with hereditary angioedema (HAE) preventing the generation of bradykinin and angioedema attacks... View more |
Prescription only
Takhzyro works by binding to a protein called kallikrein and inhibiting its activity and may be used to prevent hereditary angioedema (HAE) attacks in adults, adolescents, and children aged 2 years... View more |
Related suggestions Popular comparisons
|
|||||||||||||||
More about Haegarda (C1 esterase inhibitor (human)) | More about Takhzyro (lanadelumab) | ||||||||||||||||
Ratings & Reviews | |||||||||||||||||
Haegarda has an average rating of 8.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Takhzyro has an average rating of 9.8 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Haegarda side effects |
View all Takhzyro side effects |
||||||||||||||||
Drug Class | |||||||||||||||||
Generic Availability | |||||||||||||||||
N/A |
N/A |
||||||||||||||||
Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Haegarda prices |
View all Takhzyro prices |
||||||||||||||||
Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
Brand Names | |||||||||||||||||
Other C1 esterase inhibitor (human) brands include: Berinert, Cinryze |
N/A |
||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
152 hours |
360 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | |||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | |||||||||||||||||
A total of 51 drugs are known to interact with Haegarda:
|
A total of 3 drugs are known to interact with Takhzyro:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
Disease Interactions | |||||||||||||||||
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||
First Approval Date | |||||||||||||||||
N/A |
August 23, 2018 |
||||||||||||||||
WADA Class View classifications | |||||||||||||||||
N/A |
N/A |
||||||||||||||||
More Information | |||||||||||||||||
Patient Resources | |||||||||||||||||
Professional Resources | |||||||||||||||||
Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.